No severe complications with presbyopia inlay

Article

Implantation of an intracorneal inlay (Kamra, AcuFocus) modified the normal structure of the corneal layer of the eye but did not cause severe complications in a recent small study.

Implantation of an intracorneal inlay (Kamra, AcuFocus) modified the normal structure of the corneal layer of the eye but did not cause severe complications in a recent small study.

Professor Jorge L. Alió, MD, PhD, FEBO, and colleagues discovered that keratocyte activation was the most common negative visual outcome in their study. Confocal microscopy helps assess corneal layer changes over time after the device is inserted, they said.

The researchers embedded one of three models (ACI 7000, 7000T and 7000PDT) of the inlay in 12 eyes of 12 patients and performed confocal microscopy to examine them 6 months later. During the follow-up period, they also looked at 4 more eyes of 4 patients in whom the device was removed.

In the eyes that received the inlay, mean epithelial thickness was 54.6 ± 22 μm. The investigators detected the subbasal nerve plexus in 10 patients.

The corneal nerves per unit area were 2.73 ± 2.1 sprouts/mm2. The scientists found the branch pattern in 8 patients.

The mean keratocyte density value was 540 ± 210 cells/mm2. The researchers found a low grade of keratocyte activation in all patients.

Among the eyes in which the device was explanted, the mean wound healing opacity was 1,092.75 ± 1,877.35 μm/pixel.

The authors said they have no financial or proprietary interests related to their study.

This study can be found in the Journal of Refractive Surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.